Cargando…

Anti-MDA5 Positive Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease and Correlation between Serum Ferritin Level and Treatment Response

Clinically amyopathic dermatomyositis is an uncommon autoimmune disorder in the Middle East. The clinical picture of clinically amyopathic dermatomyositis is characterized mainly by pulmonary and dermatological manifestations. Occasionally muscle symptoms are observed as well. Serum anti-MDA5 autoan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zohar, Daniela Noa, Seluk, Lior, Yonath, Hagith, Shoenfeld, Yehuda, Kivity, Shaye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219642/ https://www.ncbi.nlm.nih.gov/pubmed/32411935 http://dx.doi.org/10.31138/mjr.31.1.75

Ejemplares similares

The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level
por: Osawa, Takeshi, et al.
Publicado: (2017)

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease
por: Levasseur, Kirsty, et al.
Publicado: (2019)

Hydroxychloroquine: From Malaria to Autoimmunity
por: Ben-Zvi, Ilan, et al.
Publicado: (2011)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
por: Mehta, Asmita A, et al.
Publicado: (2021)

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model
por: Guo, Jinqiang, et al.
Publicado: (2023)

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

Neuropsychiatric lupus: a mosaic of clinical presentations
por: Kivity, Shaye, et al.
Publicado: (2015)

Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature
por: Kivity, Shaye, et al.
Publicado: (2009)

Antibody targeting of phosphatidylserine for detection and immunotherapy of cancer
por: Zohar, Daniela Noa, et al.
Publicado: (2018)

Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease—an Auckland case series
por: Dick, Michael, et al.
Publicado: (2021)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report
por: Yamada, Kazuhiro, et al.
Publicado: (2018)

Acral Cutaneous Ulcerations and Livedo Reticularis with Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Classical Dermatomyositis
por: Wongjirattikarn, Rachot, et al.
Publicado: (2020)

Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome
por: Zuo, Yu, et al.
Publicado: (2022)

Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine
por: Kawamoto, Shinya, et al.
Publicado: (2021)

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report
por: Endo, Yushiro, et al.
Publicado: (2018)

Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient
por: Li, Zi Ying, et al.
Publicado: (2020)

Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease
por: Ye, Yan, et al.
Publicado: (2019)

Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports
por: Takahashi, Rina, et al.
Publicado: (2021)

Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: A case report and literature review
por: Lu, Ci, et al.
Publicado: (2023)

Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease
por: Li, Liubing, et al.
Publicado: (2017)

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis Complicated by Unilateral Right-sided Interstitial Lung Disease
por: Kori, Mayuko, et al.
Publicado: (2020)

Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease
por: Liang, Lin, et al.
Publicado: (2021)

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies
por: Hiramatsu, Toshiya, et al.
Publicado: (2022)

Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis
por: Li, Yuhui, et al.
Publicado: (2020)

A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Anti-MDA5 Antibody-Positive Interstitial Pneumonia with Autoimmune Features Presenting as Amyopathic Hypodermatitic Dermatomyositis: A Case Report
por: Mihailescu, Maria L., et al.
Publicado: (2021)

Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody
por: Wang, Huyan, et al.
Publicado: (2023)

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib
por: Luo, Man, et al.
Publicado: (2022)

Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity
por: Chen, Qiuhe, et al.
Publicado: (2022)

Subcutaneous Calcinosis in a Patient with Anti-MDA5 Positive Dermatomyositis
por: Hou, Ruihong, et al.
Publicado: (2021)

Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review
por: Yeung, Tsz-Wing, et al.
Publicado: (2021)

Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022)

Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
por: Ikeda, Satoshi, et al.
Publicado: (2015)

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis
por: Aissaoui, Houari, et al.
Publicado: (2021)

Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
por: Jiang, Zong, et al.
Publicado: (2023)

Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease
por: Ren, Fang-Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6u79gt8350rdembarm76lo8j9h